Journal of Investigational Allergology and Clinical Immunology最新文献

{"title":"Assessing Sensitization to Der p 23 and Inhibition of Specific IgE Using Commercial Extracts in House Dust Mite-Allergic Patients.","authors":"Patricia Bigas Peñuela, Helena Valero, Laura Viñas-Giménez, Moisés Labrador Horrillo, Victoria Cardona Dahl, Jenny Tatiana Verdesoto Viteri, Olga Luengo Sánchez","doi":"10.18176/jiaci.1121","DOIUrl":"10.18176/jiaci.1121","url":null,"abstract":"<p><strong>Background and objective: </strong>House dust mite (HDM) allergy is a leading cause of allergic rhinoconjunctivitis and asthma. Among the major HDM allergens, Der p 23 has been recognized as clinically relevant. However, allergen immunotherapy (AIT) extracts often lack defined amounts of Der p 23, which may compromise treatment in patients sensitized exclusively to this component. Objective: To determine the prevalence of monosensitization to Der p 23 among HDM-allergic patients and to assess the capacity of commercial HDM skin prick test (SPT) extracts to inhibit IgE binding.</p><p><strong>Methods: </strong>A retrospective analysis on 1700 HDM-allergic patients was carried out between 2019 and 2023. Specific IgE to Der p 1, 2, and 23 was measured using ImmunoCAP. Monosensitization to Der p 23 was defined as sIgE >0.35 kUA/L to Der p 23 and <0.10 kUA/L to Der p 1 and 2. Additional molecular profiling (ALEX microarray) was performed to confirm exclusive sensitization. sIgE inhibition assays were used to evaluate 5 commercial HDM extracts.</p><p><strong>Results: </strong>Almost two-thirds of patients (62.3%) were sensitized to Der p 23, and 3.47% (n=59) were monosensitized. Of these, 72.7% (16/22) were confirmed by ALEX. SPT extracts inhibited IgE binding in between 42% and 77% of cases depending on the manufacturer.</p><p><strong>Conclusions: </strong>The findings indicate that monosensitization to Der p 23, though relatively infrequent, affects a clinically relevant subset of patients. Commercial extracts vary in their ability to inhibit sIgE to Der p 23, underscoring the need for improved extract formulations and further research into the efficacy of AIT in this subgroup.</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"375-381"},"PeriodicalIF":6.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145349724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing Administration of Obinutuzumab: A Strategy to Minimize Infusion-Related Reactions.","authors":"Sonia Gelis, Laura Villa, Laura Magnano, Inés Monge, Rosa Muñoz-Cano","doi":"10.18176/jiaci.1193","DOIUrl":"10.18176/jiaci.1193","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"414-415"},"PeriodicalIF":6.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148609634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut Microbiota and Inflammatory Diseases: Emerging Insights and Therapeutic Perspectives. A Report From the Spanish Inflammatory Diseases Network.","authors":"Marina Pérez-Gordo, Roberto Álvarez-Lafuente, Joan Bartra, Antonio Fernández-Nebro, Rosa Muñoz-Cano, Rafael Núñez, Natalia Pérez-Sánchez, Luis Rodríguez-Rodríguez, Vicente Zanón-Moreno, José Antonio Cornejo-García","doi":"10.18176/jiaci.1196","DOIUrl":"10.18176/jiaci.1196","url":null,"abstract":"<p><p>The gut microbiota constitutes a highly complex ecosystem that plays a pivotal role in maintaining human health and modulating the immune response. Dysbiosis, an imbalance in the composition of gut microbiota, has been linked to the development and progression of multiple immune-mediated inflammatory diseases (IMIDs) and allergic disorders. Advances in sequencing and bioinformatics have enabled a deeper understanding of microbial diversity and function, revealing the crucial role of metabolites such as short-chain fatty acids (SCFAs) and secondary bile acids in sustaining epithelial integrity and immune tolerance. Altered microbiota profiles are associated with increased intestinal permeability, systemic inflammation, and autoimmune conditions including multiple sclerosis, rheumatoid arthritis, and inflammatory eye disease. Early-life establishment of microbiota is also critical, influencing susceptibility to asthma, food allergy, and other atopic conditions, such as drug hypersensitivity. Emerging therapeutic strategies aim to restore microbial balance through interventions such as the administration of probiotics, prebiotics, symbiotics, or postbiotics and fecal microbiota transplantation. Preliminary clinical evidence suggests these interventions may enhance barrier function, modulate inflammation, and improve clinical outcomes, although methodological heterogeneity and limited sample sizes constrain their application. Specific findings highlight that modulation of SCFAs and targeted bacterial taxa may influence disease activity and response to treatment. Future research should focus on identifying disease-specific microbial signatures, optimizing therapeutic formulations, and standardizing protocols for microbiota-based interventions. Integrating multiomics analyses and artificial intelligence will be essential if we are to develop predictive biomarkers and personalized therapies. Modulation of the microbiota is therefore positioned as a promising avenue in the prevention and management of IMIDs and allergic diseases.</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"335-352"},"PeriodicalIF":6.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148632563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of the Tajogaite Volcanic Eruption on Respiratory and Emotional Health in Allergic Patients: A Prospective Study.","authors":"Zulay Almeida-Sánchez, Paula Jiménez-Gallardo, Paula Aznárez-Rodríguez, Teresa Carrillo-Diaz, Felipe Rodríguez de Castro","doi":"10.18176/jiaci.1182","DOIUrl":"10.18176/jiaci.1182","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"392-394"},"PeriodicalIF":6.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147700607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eosinophilic Pleural Effusion Following Long-Term Asthma Remission Under Dupilumab Therapy: A Search for Clues Using Cytokine Analyses.","authors":"Jonas Leonhardt, Lena Gaedtke, Gülümser H Alkan, Susanne Hermann, Rosemarie Kiefl, Michael Gerckens, Alexandra Lenoir, Nikolaus Kneidinger, Diego Kauffmann-Guerrero, Jürgen Behr, Katrin Milger, Carlo Mümmler","doi":"10.18176/jiaci.1184","DOIUrl":"10.18176/jiaci.1184","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"403-406"},"PeriodicalIF":6.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147935103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Positioning of Depemokimab in Uncontrolled Severe Asthma.","authors":"Juan Carlos Miralles-López, Ismael García-Moguel, Alicia Habernau-Mena, Manuel Jorge Rial-Prado, Ana Montoro-Ferrer, Darío Antolín-Amérigo","doi":"10.18176/jiaci.1229","DOIUrl":"https://doi.org/10.18176/jiaci.1229","url":null,"abstract":"<p><p>Asthma is a chronic inflammatory disease of the airways affecting more than 300 million people worldwide. It is estimated that between 3% and 10% have severe asthma. Depemokimab is the first ultra-long-acting anti-IL-5 monoclonal antibody developed for type 2 respiratory disease, enabling administration every 26 weeks. It produces rapid and sustained reductions in blood eosinophil counts. This twice-yearly regimen markedly reduces injection frequency and may lessen treatment burden. In the replicate phase 3 SWIFT-1 and SWIFT-2 trials, depemokimab reduced the pooled annualized rate of clinically significant exacerbations by 54% and exacerbations requiring hospitalization or emergency department care by 72% compared with placebo in patients aged 12 years or older with severe eosinophilic asthma. In chronic rhinosinusitis with nasal polyps (CRSwNP), depemokimab was evaluated in the replicate phase 3 ANCHOR-1 and ANCHOR-2 trials. Both coprimary endpoints were met, and these studies provide evidence that twice-yearly depemokimab reduces the endoscopic nasal polyp score and improves nasal obstruction over 52 weeks in inadequately controlled CRSwNP. Depemokimab is approved for both severe asthma with type 2 inflammation and severe CRSwNP, making it a therapeutic option when both conditions coexist. Based on currently available evidence, depemokimab represents an additional option for patients with severe eosinophilic asthma in whom prevention of exacerbation is a major therapeutic goal. The twice-yearly dosing schedule may also be relevant when reducing treatment burden is a patient priority, although the effect of this reduction on adherence and persistence remains to be proved.</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"0"},"PeriodicalIF":6.6,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149221030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regarding \"Machine Learning Model Development and Validation in Individuals With Suggestive Hypersensitivity to Nonsteroidal Anti-inflammatory Drugs\".","authors":"Fatih Kaplan","doi":"10.18176/jiaci.1235","DOIUrl":"https://doi.org/10.18176/jiaci.1235","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"0"},"PeriodicalIF":6.6,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149129136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tezepelumab in Severe Asthma in Routine Care: Real-World Effectiveness, Clinical Remission, and Biomarkers Predicting Response in a Multicenter Study.","authors":"Diana Betancor, Victoria Villalobos-Violan, Darío Antolín-Amerigo, Leticia De Las Vecillas, Remedios Cárdenas-Contreras, Ana Elices, Mar Gandolfo-Cano, Paula Lopez-Gonzalez, Mar Moro-Moro, Beatriz Núñez-Acevedo, Mar Reaño, Teresa Robledo-Echarren, Ana Rosado-Ingelmo, Natalia Gutierrez-Albaladejo, Maria Rubio-Perez, Marcela Valverde-Monge, Maria Vazquez de la Torre, Cristina Martín-Arriscado, Rafael Pineda-Pineda, Angelica Feliu-Vila, Ismael García-Moguel, Javier Dominguez-Ortega","doi":"10.18176/jiaci.1198","DOIUrl":"https://doi.org/10.18176/jiaci.1198","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"0"},"PeriodicalIF":6.6,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149129055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ACE Inhibitor-Induced Isolated Visceral Angioedema: A Diagnostic Pitfall Mimicking Inflammatory Bowel Disease.","authors":"Stefan Cimbollek, Pilar Silva-Ruiz, Luis Fernández Moya, Teresa de Aramburu Mera, Krasimira Baynova","doi":"10.18176/jiaci.1202","DOIUrl":"https://doi.org/10.18176/jiaci.1202","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"0"},"PeriodicalIF":6.6,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149117774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allergy to the Fatty Part of Hemp Seed.","authors":"Alicia Moncada Salinero, Tania Galán Díez, Fernando Pineda de la Losa, Mª Dolores Alonso-Díaz de Durana, Teresa Alfaya Arias","doi":"10.18176/jiaci.1209","DOIUrl":"https://doi.org/10.18176/jiaci.1209","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"0"},"PeriodicalIF":6.6,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149117807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}